Rachel E. Sanborn
About
Rachel E. Sanborn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology.
According to data from OpenAlex, Rachel E. Sanborn has authored 154 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 60 papers in Pulmonary and Respiratory Medicine and 35 papers in Immunology. Recurrent topics in Rachel E. Sanborn's work include Cancer Immunotherapy and Biomarkers (56 papers), Lung Cancer Treatments and Mutations (45 papers) and CAR-T cell therapy research (31 papers). Rachel E. Sanborn is often cited by papers focused on Cancer Immunotherapy and Biomarkers (56 papers), Lung Cancer Treatments and Mutations (45 papers) and CAR-T cell therapy research (31 papers). Rachel E. Sanborn collaborates with scholars based in United States, United Kingdom and Spain. Rachel E. Sanborn's co-authors include Ashok Gupta, Scott Antonia, Naiyer A. Rizvi, Ani Sarkis Balmanoukian, Joyson Karakunnel, Keith E. Steele, Yu Gu, Sarah B. Goldberg, Rajesh Narwal and Neil H. Segal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Rachel E. Sanborn
148 papers receiving 3.6k citations
Hit Papers
Peers
Rachel E. Sanborn
Gene Grant Finley United States
Erminia Massarelli United States
Carlos Gomez‐Roca France
Drew Rasco United States
Peter Langmuir United States
Osama E. Rahma United States
Dimitrios Bafaloukos Greece
Alice Pons United States
Achim Rittmeyer United States
Bilal Piperdi United States
Citations per year, relative to Rachel E. Sanborn Rachel E. Sanborn (= 1×)
peers
Gene Grant Finley
Countries citing papers authored by Rachel E. Sanborn
Since
Specialization
Citations
This map shows the geographic impact of Rachel E. Sanborn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel E. Sanborn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel E. Sanborn more than expected).
Fields of papers citing papers by Rachel E. Sanborn
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rachel E. Sanborn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel E. Sanborn. The network helps show where Rachel E. Sanborn may publish in the future.
Co-authorship network of co-authors of Rachel E. Sanborn
This figure shows the co-authorship network connecting the top 25 collaborators of Rachel E. Sanborn. A scholar is included among the top collaborators of Rachel E. Sanborn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel E. Sanborn. Rachel E. Sanborn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Beltran, Himisha, Prantesh Jain, Erin L. Schenk, et al.. (2025). 2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers. Annals of Oncology. 36. S1367–S1367.
2.
Ramalingam, Suresh S., Michael B. Thomas, Rachel E. Sanborn, et al.. (2025). OA05.04 A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC: ZEAL-1L. Journal of Thoracic Oncology. 20(10). S20–S21.
3.
Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505.
4.
Fu, Siqing, et al.. (2024). Abstract CT116: Preclinical antitumor activity and first-in-human phase I study of NB004/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors. Cancer Research. 84(7_Supplement). CT116–CT116.
5.
Vita, Alessandro De, Douglas Hanes, Bela Bapat, et al.. (2024). Clinical impact for advanced non-small-cell lung cancer patients tested using comprehensive genomic profiling at a large USA health care system. SHILAP Revista de lepidopterología. 5. 100057–100057.
6.
Peters, Solange, Antoine Hollebecque, Kartik Sehgal, et al.. (2024). Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).. Journal of Clinical Oncology. 42(16_suppl). 8521–8521.
7.
Sabari, Joshua K., Nicolas Girard, Aaron S. Mansfield, et al.. (2024). Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer. Future Oncology. 20(32). 2409–2421.
8.
Zhou, Caicun, Akira Ono, Hidetoshi Hayashi, et al.. (2024). 635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC. Annals of Oncology. 35. S1638–S1639.
9.
Sanborn, Rachel E., Minal Patel, Jordi Rodón, et al.. (2024). 991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors. Annals of Oncology. 35. S675–S676.
10.
Choudhury, Noura J., Himisha Beltran, Erin L. Schenk, et al.. (2024). OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S32–S33.
11.
Park, Jong Chul, David Berz, Manish Sharma, et al.. (2023). 742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors. SHILAP Revista de lepidopterología. A836–A837.
12.
Girard, N., K. Park, Kun Tang, et al.. (2023). LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study. Annals of Oncology. 34. S1304–S1304.
13.
Choudhury, Noura J., Prantesh Jain, Afshin Dowlati, et al.. (2023). 698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN). Annals of Oncology. 34. S486–S486.
14.
Sen, Shiraj, Alexander I. Spira, David Sommerhalder, et al.. (2023). 1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. Annals of Oncology. 34. S649–S650.
15.
Park, Keunchil, Joshua K. Sabari, Eric B. Haura, et al.. (2022). MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study. Annals of Oncology. 33. S482–S482.
16.
Johnson, Melissa L., Anthony B. El-Khoueiry, Navid Hafez, et al.. (2021). Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 27(16). 4521–4530.
17.
Epstein, Robert S., et al.. (2021). Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers. Journal of Medical Economics. 25(1). 108–118.
18.
Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.. Journal of Thoracic Oncology.
19.
Cho, Byoung Chul, Dongwook Kim, Jin Sun Lee, et al.. (2020). 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Annals of Oncology. 31. S813–S813.
20.
Horn, Leora, Jeffrey R. Infante, Karen L. Reckamp, et al.. (2018). Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research. 24(12). 2771–2779.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gene Grant Finley Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Carlos Gomez‐Roca Breakdown of academic impact, for papers by Drew Rasco Breakdown of academic impact, for papers by Peter Langmuir Breakdown of academic impact, for papers by Osama E. Rahma Breakdown of academic impact, for papers by Dimitrios Bafaloukos Breakdown of academic impact, for papers by Alice Pons Breakdown of academic impact, for papers by Achim Rittmeyer Breakdown of academic impact, for papers by Bilal Piperdi